Your browser doesn't support javascript.
CalScope: Monitoring SARS-CoV-2 Seroprevalence from Vaccination and Prior Infection in Adults and Children in California May 2021 to July 2021
Megha L. Mehrotra; Esther Lim; Katherine Lamba; Amanda Kamali; Kristina W. Lai; Erika Meza; Irvin Szeto; Peter Robinson; Cheng-ting Tsai; David Gebhart; Noemi Fonseca; Andrew B. Martin; Catherine Ley; Steve Scherf; James Watt; David Seftel; Julie Parsonnet; Seema Jain.
  • Megha L. Mehrotra; California Department of Public Health
  • Esther Lim; California Department of Public Health
  • Katherine Lamba; California Department of Public Health
  • Amanda Kamali; California Department of Public Health
  • Kristina W. Lai; California Department of Public Health
  • Erika Meza; California Department of Public Health
  • Irvin Szeto; Stanford University
  • Peter Robinson; Enable Biosciences
  • Cheng-ting Tsai; Enable Biosciences
  • David Gebhart; Enable Biosciences
  • Noemi Fonseca; Enable Biosciences
  • Andrew B. Martin; Stanford University
  • Catherine Ley; Stanford University
  • Steve Scherf; Gauss Surgical
  • James Watt; California Department of Public Health
  • David Seftel; Enable Biosciences
  • Julie Parsonnet; Stanford University
  • Seema Jain; California Department of Public Health
Preprint Dans Anglais | medRxiv | ID: ppmedrxiv-21267565
ABSTRACT
ImportanceUnderstanding how SARS-CoV-2 seroprevalence varies regionally across California is critical to the public health response to the pandemic. ObjectiveTo estimate how many Californians have antibodies against SARS-CoV-2 from prior infection or vaccination. DesignWave 1 of CalScope a repeated cross-sectional serosurvey of adults and children enrolled between April 20, 2021 and June 16, 2021. SettingA population-based random sample of households in seven counties in California (Alameda, El Dorado, Kern, Los Angeles, Monterey, San Diego, and Shasta) were invited to complete an at-home SARS-CoV-2 antibody test and survey instrument. ParticipantsInvitations were sent to 200,000 randomly selected households in the seven counties. From each household, 1 adult (18 years and older) and 1 child (aged 6 months to 17 years) could enroll in the study. There were no exclusion criteria. Main Outcome(s) and MeasuresAll specimens were tested for antibodies against the nucleocapsid and spike proteins of SARS-CoV-2. The primary outcome was serostatus category, which was determined based on antibody test results and self-reported vaccination status seronegative, antibodies from infection only, antibodies from infection and vaccination, and antibodies from vaccination alone. We used inverse probability of selection weights and iterative proportional fitting to account for non-response. Results11,161 households enrolled in wave 1 of CalScope, with 7,483 adults and 1,375 children completing antibody testing. As of June 2021, 27% (95%CI [23%, 31%]) of adults and 30% (95%CI [24%, 36%]) of children had evidence of prior SARS-CoV-2 infection; 33% (95%CI [28%, 37%]) of adults and 57% (95%CI [48%, 66%]) of children were seronegative. Serostatus varied regionally. Californians 65 years or older were most likely to have antibodies from vaccine alone (59%; 95%CI [48%, 69%]) and children between 5-11 years old were most likely to have antibodies from prior infection alone (36%; 95%CI [21%, 52%]). Conclusions and RelevanceAs of June 2021, a third of adults in California and most children under 18 remained seronegative. Seroprevalence varied regionally and by demographic group, suggesting that some regions or populations might remain more vulnerable to subsequent surges than others. Key PointsO_ST_ABSQuestionC_ST_ABSWhat is the prevalence of vaccine and infection derived antibodies against SARS-CoV-2 in adults and children in California? FindingsIn this population-based serosurvey that included 11,161 households, as of June 2021, 33% of adults and 57% of children were seronegative; 18% of adults and 26% of children had antibodies from infection alone; 9% of adults and 5% of children had antibodies from both infection and vaccination; and 41% of adults and 13% of children had antibodies from vaccination alone. MeaningSerostatus varied considerably across geographic regions, suggesting that certain areas might be at increased risk for future COVID-19 surges.
Texte intégral: Disponible Collection: Preprints Base de données: medRxiv Type d'étude: Essai contrôlé randomisé / Facteurs de risque Les sujets: Vaccins langue: Anglais Année: 2021 Type de document: Preprint

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS

Texte intégral: Disponible Collection: Preprints Base de données: medRxiv Type d'étude: Essai contrôlé randomisé / Facteurs de risque Les sujets: Vaccins langue: Anglais Année: 2021 Type de document: Preprint